VERVE THERAPEUTICS, INC.
CIK 0001840574
Revenue (TTM)
—
Q1 May 2025
Net Income (TTM)
−$179.71M
+0.7% YoY
Q1 May 2025
EPS Diluted (TTM)
−$2.12
+24.7% YoY
Q1 May 2025
Gross Margin
—
Q1 May 2025
Operating Margin
—
Q1 May 2025
Net Margin
—
Q1 May 2025
Free Cash Flow (TTM)
−$161.47M
Q1 May 2025
Cash
$96.55M
Q1 May 2025
Total Debt
—
Q1 May 2025
Shares Outstanding
89.14M sh
Q1 May 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.